CLIENTRON-CORP.
15.10.2019 15:02:04 CEST | Business Wire | Press release
Clientron Corp., a leading global provider of Thin Client, POS and embedded systems, introduces the brand new all-in-one Thin Client TC238 that features a 23.8” display with fanless and ultra-slim enclosure, and system designed with the concept of Intel® Smart Display Module (Intel® SDM) for optimized display computing. The TC238 AiO thin client runs on client-server architecture and can be implemented with major existing VDI protocols to deliver the best user computing experience for virtual desktop solutions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191015005364/en/
Easy deployment and maintenance to optimize user experience
The TC238 AiO thin client designed with Intel® Smart Display Module (SDM-Large) featuring open pluggable, flexible integration, easy deployment and maintenance design to reduce total cost of ownership.
Energy-efficient and high performance for End user computing
Powered by high performance and power efficient Intel® Braswell x5-E8000 quad core processors, the TC238 AiO thin client supports DDR3L-1600 memory, storage options including mSATA SSD and on-board eMMC storages as manufacturing optional. The I/O connectors include two USB3.2 Gen 1 ports, two USB 2.0 ports, one DisplayPort, one DVI, audio ports as well as networking ability with a M.2 interface for WiFi and Bluetooth functionality.
High-density viewing and space-saving benefits
Featuring ultra-slim enclosure, the TC238 AiO thin client supports 23.8” full HD display and anti-glare panel for comfortable reading. Powered by one wire, it offers streamline and space-saving benefits for operations. In additions, it supports 4K display output to give users a rich, high-density viewing on external monitor.
Enhanced System Security & Virtual Desktop solutions
The TC238 thin client supports Trusted Platform Module (TPM) by manufacturing optional for secure data protection. Moreover, it supports all mainstream virtual desktop protocols including Microsoft RDP/ RemoteFX/WVD, Citrix HDX, and VMware Horizon View to ensure high availability and seamless communication with other applications.
The AiO TC238 thin client features highlight:
- Power-efficient Intel® Braswell x5-E8000 Quad Core Processor with fanless design
- Ultra-slim enclosure with open pluggable Intel® Smart Display Module (SDM-Large)
- Stylish 23.8” Full HD display with LED backlight
- Support up to 4K resolution for external display
- Able to rotate screen to upright position with optional stand
- Adjustable display swivel and tilt angle
- Support two USB 3.2 Gen 1, two USB 2.0, Giga LAN
- Support VESA mount for various mounting solutions
- Support Kensington lock
- Optional Wi-Fi module (M.2 2230 E Key Socket)
- Factory option for eMMC and TPM
The Clientron AiO Thin Client TC238 is available now. For more product details, please contact Clientron sales or visit our website www.clientron.com
About Clientron
Clientron is dedicated to be the professional thin client, POS, Automotive Electronics and embedded computing ODM provider for over 15 years. With providing Design, Manufacturing and Service support abilities for embedded computing, Clientron is your best embedded solution partner to empower more efficiency and safety for your e-World. Visit us at www.clientron.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20191015005364/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom